

BEST OF ASCO®
OFFICIALLY LICENSED



**AMERICAN
UNIVERSITY
OF BEIRUT**



**NAFI K. BASILE
CANCER INSTITUTE**

AMERICAN UNIVERSITY OF BEIRUT
معهد نافي ك. باسيل للسرطان في الجامعة الأمريكية في بيروت



Lebanese Society of Medical Oncology
الجمعية اللبنانية لأطباء الأورام الخبيث



رابطة الأطباء العرب لمكافحة السرطان
Arab Medical Association Against Cancer

THE 18th BEST OF ASCO23

July 7 - 8, 2023 | AUBMC, Beirut, Lebanon

Hybrid Meeting

Daniel ACC Conference Rooms

American University of Beirut Medical Center (AUBMC)

Best of ASCO Lebanon Chair: Nagi S. El Saghir, MD, FACP, FASCO

Organized by AUBMC

Licensed by ASCO

In collaboration with LSMO, AMAAC



WELCOME ADDRESS FROM THE PRESIDENT



Dear Colleagues and Friends,

It is my great pleasure to invite you to our **18th Annual Best of ASCO Lebanon Meeting** that we will hold this year again in HYBRID format. Speakers and Attendees in Lebanon will be in-person, speakers and attendees from overseas will be virtual.

Best of ASCO23 is licensed by the American Society of Clinical Oncology (ASCO), and we will hold it Lebanon on **Friday-Saturday July 7-8, 2023** in HYBRID from the Daniel ACC Building Conference Rooms at the American University of Beirut Medical Center (AUBMC). Best of ASCO 2023 is organized by the Division of Hematology Oncology of the Department of Internal Medicine and the Naef K. Basile Cancer Institute of the American University of Beirut, in collaboration with the Lebanese Society of Medical Oncology (LSMO) and the Arab Medical Association Against Cancer (AMAAC)

The Oncology field is witnessing outstanding advances for research and patient management, of which many were presented and discussed recently at ASCO in Chicago in June 2023. We will have many practice-changing abstracts as well as great hypothesis generating abstracts that were selected for presentation at Best Of ASCO23.

This year we changed the format and decided to have abstracts presented by experts in their fields, many by ASCO presenters themselves, and have ample time for Panel discussions. The Chairs of sessions are chosen as Chairs to very briefly introduce speakers, and as Panel Discussants asked to run structured discussions and come up with take home messages and recommendations.

Please note that Advance Registration is free and mandatory. Deadline for registration is July 5, 2023.

Nagi S. El Saghir, MD, FACP, FASCO

Professor & Head of Hematology-Oncology, AUBMC (Email: ns23@aub.edu.lb)

Chair, Best of ASCO Lebanon

COMMITTEES

ORGANIZED BY:

Division of Hematology Oncology and the Naef Basile Cancer Institute (NKBCI) of the American University of Beirut Medical Center (AUBMC)

IN COLLABORATION WITH:

The Lebanese Society of Medical Oncology (LSMO) and the Arab Medical Association Against Cancer (AMAAC)

LICENSED BY:

The American Society of Clinical Oncology

BEST OF ASCO LEBANON CHAIR:

Nagi S. El Saghir, MD, FACP, FASCO

BEST OF ASCO LEBANON PLANNING COMMITTEE:

Nagi S. El Saghir, MD, FACP, FASCO (Chair) - Hikmat Abdel-Razeq, MD - Reem Abdallah, MD - Ghassan Abou-Alfa, MD, MBA - Iman Abou Dalle, MD - Albert El Hajj, MD - Hiba Moukadem, MD - Arafat Tfayli, MD

SPEAKERS

Ghassan Abou-Alfa, MD, MBA

Julio Garcia Aguilar, MD

Ali Bazarbachi, MD, PhD

Etienne Brain, MD, PhD

David Cameron, MD

Toni Choueiri, MD

Javier Cortes, MD

Nagi S. El Saghir, MD

Fadlo Khuri, MD

Mohamad Mohty, MD, PhD

Suresh Ramalingam, MD

Morgan Roupret, MD

Samer Salah, MD

Mian Shahzad, MD

Hussein Tawbi, MD, PhD

Bassem Youssef, MD

Memorial Sloan Kettering Cancer Center, New York, USA

Memorial Sloan Kettering Cancer Center, New York, USA

American University of Beirut, Medical Center, Beirut, Lebanon

Institut Curie - Hôpital René Huguenin, Paris, France

Western General Hospital, Edinburgh, UK

Dana - Farber Cancer Institute, Boston, USA

International Breast Cancer Centre, Madrid and Barcelona, Spain

American University of Beirut, Medical Center, Beirut, Lebanon

American University of Beirut, Medical Center, Beirut, Lebanon

H. St-Antoine, Sorbonne Université, INSERM (UMR) 938, Paris, France

Winship Cancer Institute of Emory University, Atlanta, USA

Hôpital Pitié-Salpêtrière, Paris, France

King Hussein Cancer Center, Aman, Jordan

Lee Moffit Cancer Center, Tampa, FL, USA

MD Anderson Cancer Center, Houston, TX, USA

American University of Beirut, Medical Center, Beirut, Lebanon

PROGRAM



FRIDAY JULY 7, 2023

10:20 - 10:30

Welcome Address

Nagi S. El Saghir, MD, FACP, FASCO - President, Best of ASCO Lebanon
Roger Khater, MD - President, Lebanese Society of Medical Oncology
Sami Khatib, MD - President, Arab Medical Association Against Cancer



Breast Cancer - Local/Regional

Chairs: Hikmat Abdel-Razeq, MD - Omalkhair Abulhair, MD - Hamdy Azim, MD - Nagi El Saghir, MD

10:30 - 10:40

Abstract LBA500: Phase III NATALEE Trial of Ribociclib + Endocrine Therapy as Adjuvant Treatment in Patients with HR+/HER2 Early Breast Cancer. D. Slamon, MD | **Presented by David Cameron, MD**

10:40 - 10:50

Abstract 501: Efficacy and Safety Results by Age in Monarche: Adjuvant Abemaciclib Combined with Endocrine Therapy (ET) in Patients with HR+, HER2-, Node-Positive, High-Risk Early Breast Cancer EBC. E. Hamilton, MD | **Presented by Etienne Brain, MD, PhD**

10:50 - 11:00

Abstract 503: Effects of Ovarian Ablation or Suppression on Breast Cancer Recurrence and Survival: Patient-Level Meta-Analysis of 14,993 Pre-Menopausal Women in 25 Randomized trials. R. Gray, MD | **Presented by Nagi S. El Saghir, MD**

11:00 - 11:20



Panel Discussion: David Cameron, MD - Etienne Brain, MD, PhD - Hikmat Abdel-Razeq, MD - Omalkhair Abulhair, MD
Hamdy Azim, MD - Nagi El Saghir, MD

11:20 - 11:35



Coffee Break

PROGRAM



FRIDAY JULY 7, 2023



Breast Cancer - Metastatic

Chairs: Sana Al-Sukhun, MD - Meteb Al-Fohaidi, MD - Hesham El-Ghazaly, MD - Alaa Kandil, MD

11:35 - 11:45

Abstract LBA1000: Primary Outcome Analysis of the Phase 3 SONIA Trial (BOOG 2017-03) on Selecting the Optimal Position of Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitors for Patients with Hormone Receptor-Positive (HR+), HER2-Negative (HER2-) Advanced Breast Cancer (ABC) G. Sonke, MD | **Presented by Ahmad Awada, MD**

11:45 - 11:55

Abstract 1003: Final Overall Survival (OS) Analysis from the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (pts) with Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Metastatic Breast Cancer (mBC) Tolaney, MD
Presented by Javier Cortes, MD

11:55 - 12:15



Panel Discussion: Ahmad Awada, MD - Javier Cortes, MD - Sana Al-Sukhun, MD - Meteb Al-Fohaidi, MD - Alaa Kandil, MD
Hesham El-Ghazaly, MD - Ali Bazarbachi, MD, PhD

12:15 - 13:00

Menarini Symposium

ER+/HER2- Breast Cancer: Advances in Endocrine Therapy and New Treatment Options | **Hassan Ghazal, MD**

Chairperson: Arafat Tfayli, MD

13:00 - 14:00



Lunch Break

PROGRAM



FRIDAY JULY 7, 2023



Gastrointestinal Cancer - Colorectal, Pancreatic and Hepatobiliary

Chairs: Fadi Farhat, MD - Marwan Ghosn, MD - Mohamad Khalife, MD - Ali Shamseddine, MD

14:00 - 14:15

Abstract LBA2 PROSPECT: A Randomized Phase III Trial of Neoadjuvant Chemoradiation Versus Neoadjuvant FOLFOX Chemotherapy with Selective Use of Chemoradiation, Followed by Total Mesorectal Excision (TME) for Treatment of Locally Advanced Rectal Cancer (LARC) (Alliance N1048) Plenary Session by D. Schrag, MD | **Presented by Julio Garcia Aguilar, MD**

14:15 - 14:25

Abstract 3520: Sustained Organ Preservation in Rectal Cancer Patients Treated with Total Neoadjuvant Therapy: Long-Term Results of the OPRA Trial. F. Verweij, MD | **Presented by Julio Garcia Aguilar, MD**

14:25 - 14:35

Abstract 4006: Liposomal Irinotecan + 5-Fluorouracil/Leucovorin + Oxaliplatin (NALIRIFOX) Versus Bab-Paclitaxel + Gemcitabine in Treatment-Naive Patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): 12- and 18-Month Survival Rates from the Phase 3 NAPOLI 3 Trial. E. O'Reilly, MD | **Presented by Ghassan Abou Alfa, MD, MBA**

14:35 - 14:45

Abstract 4008: Results from the Pivotal Phase (Ph) 2b HERIZON-BTC-01 Study: Zanidatamab in Previously-Treated HER2 Amplified Biliary Tract Cancer (BTC). S. Pant, MD | **Presented by Ghassan Abou-Alfa, MD, MBA**

14:45 - 15:10



Panel Discussion: Julio Garcia Aguilar, MD - Ghassan Abou Alfa, MD, MBA - Fadi Farhat, MD - Marwan Ghosn, MD - Mohamad Khalife, MD - Ali Shamseddine, MD

15:10 - 15:45

MSD Symposium

Emerging Role of Adjuvant IO in Early Stage NSCLC: Latest Updates | **Prof. Maximilian Hochmair**

PROGRAM



FRIDAY JULY 7, 2023



Non Small Cell Lung Cancer, Local, Local, Regional and Metastatic and Mesothelioma

Chairs: Taher Abu Hejleh, MD - Adda Bounedjar, MD - Samir Eid Shehata, MD - Arafat Tfayli, MD - Fadi Karak, MD

15:45 - 16:00

Abstract LBA3: Overall Survival Analysis from the ADAURA Trial of Adjuvant Osimertinib in Patients with Resected EGFR Mutated (EGFRm) Stage IB-IIIa Non-Small Cell Lung Cancer (NSCLC). Plenary Session by R. Herbst, MD

Presented by Suresh Ramalingham, MD

16:00 - 16:15

Abstract LBA100: KEYNOTE-671, Randomized, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Platinum-Based Chemotherapy Followed by Resection and Pembrolizumab or Placebo for Early Stage NSCLC. H. Wakelee, MD

Presented by Suresh Ramalingham, MD



Non-Small Cell Lung Cancer - Metastatic and Mesothelioma

Chairs: Taher Abu Hejleh, MD - Adda Bounedjar, MD - Samir Eid Shehata, MD - Arafat Tfayli, MD - Fadi Karak, MD

16:15 - 16:25

Abstract LBA9000: Pemetrexed and Platinum with or without Pembrolizumab for Tyrosine Kinase Inhibitor (TKI)-Resistant, EGFR-Mutant, Metastatic Nonsquamous NSCLC: Phase 3 KEYNOTE-789 Study. J. Yang, MD | **Presented by Fadlo Khuri, MD**

16:25 - 16:35

Abstract LBA8505: IND227 Phase III (P3) Study of Cisplatin/Pemetrexed (CP) with or without Pembrolizumab (Pembro) in Patients (pts) with Malignant Pleural Mesothelioma (PM): A CCTG, NCIN, and IFCT Trial. Q. Chu, MD | **Presented by Fadlo Khuri, MD**

16:35 - 16:55




Panel Discussion: Suresh Ramalingham, MD - Fadlo Khuri, MD - Taher Abu Hejleh, MD - Adda Bounedjar, MD
Samir Eid Shehata, MD - Arafat Tfayli, MD - Fadi Karak, MD

PROGRAM




FRIDAY JULY 7, 2023


➤ **Melanoma and Skin Cancers** Chairs: Hazem Assi, MD - Fadi Nasr, MD - Mona Ayoubi, MD - Mohamad Kadri, MD - Jihane Abou Rahal, MD

- 16:55 - 17:05 Abstract LBA9503: Distant Metastasis-Free Survival Results from the Randomized, Phase 2 mRNA-4157-P201/KEYNOTE-942 Trial
A. Khattak, MD | **Presented by Hussein Tawbi, MD, PhD**
- 17:05 - 17:15 Abstract LBA9505: Pembrolizumab Versus Placebo as Adjuvant Therapy in Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase 3 KEYNOTE-716 Study. J. Luke, MD | **Presented by Hussein Tawbi, MD, PhD**
- 17:15 - 17:35  **Panel Discussion:** Hussein Tawbi, MD, PhD - Hazem Assi, MD - Fadi Nasr, MD - Mona Ayoubi, MD - Mohamad Kadri, MD
Jihane Abou Rahal, MD

➤ **CNS Tumors** Chairs: Hazem Assi, MD - Hussein Darwish, MD - Francois Kamar, MD - Ibrahim Saikali, MD - Toufic Eid, MD

- 17:35 - 17:50 Abstract LBA1 INDIGO: A Global, Randomized, Double-Blinded, Phase 3 Study of Vorasidenib Versus Placebo in Patients with Residual or Recurrent Grade 2 Glioma with an IDH1/2 Mutation. Plenary Session by I. Mellinghoff | **Presented by**
- 17:50 - 18:10  **Panel Discussion:** Hazem Assi, MD - Hussein Darwish, MD - Francois Kamar, MD - Ibrahim Saikali, MD - Toufic Eid, MD

PROGRAM



SATURDAY JULY 8, 2023



Hematologic Malignancies - Plasma Cell Dyscrasias

Chairs: Maha Manachi, MD - Jean Cheikh, MD - David Wehbe, MD - Hady Ghanem, MD

10:00- 10:10

Abstract LBA106: First Phase 3 Results from CARTITUDE-4: Cilta-Cel Versus Standard of Care (PVd or DPd) in Lenalidomide-Refractory Multiple Myeloma. B. Dakal, MD | **Presented by Mohamad Mohty, MD, PhD**

10:10 - 10:20

Abstract 8000: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Elotuzumab and KRd in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Post-Induction Response and MRD Results from an Open-Label Randomized Phase 3 Study. S. Knop, MD | **Presented by Mohamad Mohty, MD, PhD**

10:20 - 10:40



Panel Discussion: Mohamad Mohty, MD, PhD - Maha Manachi, MD - Jean Cheikh, MD - David Wehbe, MD - Hady Ghanem, MD



Hematologic Malignancies - Lymphoma

Chairs: Imane Abou Dalle, MD - Fadi Nasr, MD - Ahmad Ibrahim, MD - Ola Khorshid, MD

10:40 - 10:50

Abstract LBA4: SWOG S1826 A Randomized Study of Nivolumab(N)-AVD Versus Brentuximab Vedotin(BV)-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL) Plenary Session by A. Herrera, MD | **Presented by Ali Bazarbachi, MD, PhD**

10:50 - 11:00

Abstract 7508: Very Long-Term Follow-up of Rituximab Maintenance in Young Patients with Mantle Cell Lymphoma Included in the LYMA Trial, a LYSA Study. C. Sarkozy, MD | **Presented by Ali Bazarbachi, MD, PhD**

11:00 - 11:20



Panel Discussion: Imane Abou Dalle, MD - Fadi Nasr, MD - Ahmad Ibrahim, MD - Ola Khorshid, MD - Ali Bazarbachi, MD, PhD

11:20 - 11:35



Coffee Break

11:35 - 12:10

Roche Symposium

Highlighting the Value of PHESGO in HER2+ Breast Cancer | **Marwan Ghosn, MD**

PROGRAM



SATURDAY JULY 8, 2023



Gynecologic Cancers

Chairs: Reem Abdallah, MD - Hiba Moukadem, MD - Ibtissam Saadeddin, MD - Muhieddine Seoud, MD - David Atallah, MD

12:10 - 12:20

Abstract 5503: Dostarlimab for Primary Advanced or Recurrent (A/R) Endometrial Cancer (EC): Outcomes by Blinded Independent Centra Review (BICR) of the RUBY Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). M. Powell, MD

Presented by Mian Shahzad, MD

12:20 - 12:30

Abstract LBA5511: An International Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection (RH) vs Simple Hysterectomy and Pelvic Node Dissection (SH) in Patients with Low-Risk Early-Stage Cervical Cancer (LRESCC) A Gynecologic Cancer Intergroup Study Led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE) M. Plante, MD

Presented by Mian Shahzad, MD

12:30 - 12:50



Panel Discussion: Reem Abdallah, MD - Hiba Moukadem, MD - Ibtissam Saadeddin, MD - Mian Shahzad, MD
Muhieddine Seoud, MD - David Atallah, MD

13:00 - 14:00



Lunch Break

PROGRAM



SATURDAY JULY 8, 2023



Kidney/Bladder Cancer

Chairs: Georges Chahine, MD - Joseph Makdessi, MD - Mohamad Bulbul, MD - Ahmed Younes, MD

14:00 - 14:10

Abstract LBA4500: Efficacy and Safety of Atezolizumab Plus Cabozantinib vs Cabozantinib Alone After Progression with Prior Immune Checkpoint Inhibitor (ICI) Treatment in Metastatic Renal Cell Carcinoma (RCC): Primary PFS Analysis from the Phase 3, Randomized, Open-Label CONTACT-03 Study. T. Choueiri, MD | **Presented by Toni Choueiri, MD**

14:10 - 14:20

Abstract LBA4501: Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Therapy for Advanced Clear Cell Renal Cell Carcinoma: 5-Year Analysis Of Keynote-426. B. Rini, MD | **Presented by Toni Choueiri, MD**

14:20 - 14:40



Panel Discussion: Toni Choueiri, MD - Georges Chahine, MD - Joseph Makdessi, MD - Mohamad Bulbul, MD - Ahmed Younes, MD



Bladder Cancers

Chairs: Albert Hajj, MD - Joseph Makdessi, MD - Sally Temraz, MD

14:40 - 14:50

Abstract LBA4507: Multicenter Randomized Phase III Trial of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (dd-MVAC) or Gemcitabine and Cisplatin (GC) as Perioperative Chemotherapy for Muscle-Invasive Bladder Cancer (MIBC): Overall Survival (OS) Data at 5 Years in the GETUG/AFU V05 VESPER Trial. C. Pfister, MD | **Presented by Morgan Roupret, MD**

14:50 - 15:00

Abstract 4508 SWOG S1011: A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer S. Lerner, MD | **Presented by Morgan Roupret, MD**

15:00 - 15:20



Panel Discussion: Morgan Roupret, MD - Albert Hajj, MD - Joseph Makdessi, MD - Sally Temraz, MD

PROGRAM



SATURDAY JULY 8, 2023



Prostate/Testicular/Penile Cancers

Chairs: Albert Hajj, MD - Joseph Kattan, MD - Deborah Mukherji, MD - Yousri Rostom, MD

15:20 - 15:30

Abstract 5004: TALAPRO-2, Phase 3 Study of Talazoparib (TALA) + Enzalutamide (ENZA) Versus Placebo (PBO) + ENZA as First-Line (1L) Treatment for Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Harboring Homologous Recombination Repair (HRR) Gene Alterations. **N. Agarwal, MD | Presented by Samer Salah, MD**

15:30 - 15:40

Abstract LBA5000: Prostate Irradiation in Men with De Novo, Low-Volume, Metastatic, Castration-Sensitive Prostate Cancer (mCSPC): Results of PEACE-1, a Phase 3 Randomized Trial with a 2x2 Design. **A. Bossi, MD | Presented by Bassem Youssef, MD**

15:40 - 16:00



Panel Discussion: Albert Hajj, MD - Joseph Kattan, MD - Deborah Mukherji, MD - Yousri Rostom, MD - Bassem Youssef, MD
Samer Salah, MD

16:00

ADJOURN



A Menarini Group Company



Pierre Fabre



Organized by:



LEBANON

4th Floor, Qubic Center
Daoud Ammoun Street
Horsh Tabet - Sin El Fil
P.O. Box: 90-361 Beirut
Tel: +961 1 510880/1/2/3
Mobile: +961 71 103123

UAE

DMCC Business Centre
Almas Tower
Jumeirah Lakes
Dubai, United Arab Emirates
Unit No: 3820
Mobile: +971 50 9110475

KUWAIT

Mezzanine floor,
Aliya Complex
Salem Al Mubarak St
Block 2, Salmiya - Kuwait
Tel: +965 6556 7669

